MDM2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is altered in 71.43% of rhabdoid tumor of the kidney patients [2].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for rhabdoid tumor of the kidney, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [3].